P58
IPK is a tetratricopeptide repeat-containing cochaperone that is involved in stress-activated cellular pathways and that inhibits the activity of protein kinase PKR, a primary mediator of the antiviral and antiproliferative properties of interferon. To gain better insight into the molecular actions of P58 IPK , we generated NIH 3T3 cell lines expressing either wild-type P58 IPK or a P58 IPK deletion mutant, ⌬TPR6, that does not bind to or inhibit PKR. When treated with double-stranded RNA (dsRNA), ⌬TPR6-expressing cells exhibited a significant increase in eukaryotic initiation factor 2␣ phosphorylation and NF-B activation, indicating a functional PKR. In contrast, both of these PKR-dependent events were blocked by the overexpression of wild-type P58 IPK . In addition, the P58 IPK cell line, but not the ⌬TPR6 cell line, was resistant to dsRNA-induced apoptosis. Together, these findings demonstrate that P58 IPK regulates dsRNA signaling pathways by inhibiting multiple PKR-dependent functions. In contrast, both the P58 IPK and ⌬TPR6 cell lines were resistant to tumor necrosis factor alpha-induced apoptosis, suggesting that P58 IPK may function as a more general suppressor of programmed cell death independently of its PKR-inhibitory properties. In accordance with this hypothesis, although PKR remained active in ⌬TPR6-expressing cells, the ⌬TPR6 cell line displayed a transformed phenotype and was tumorigenic in nude mice. Thus, the antiapoptotic function of P58 IPK may be an important factor in its ability to malignantly transform cells.
IPK , a member of the tetratricopeptide repeat (TPR) family of proteins (31) , is a cellular inhibitor of the interferoninduced protein kinase PKR. This property of P58 IPK has been exploited by influenza virus, which recruits P58 IPK to repress PKR-mediated eukaryotic initiation factor 2␣ (eIF-2␣) phosphorylation (32, 33) , thereby enabling influenza virus to evade the host antiviral response by maintaining a high level of protein synthesis. P58
IPK also has growth-regulatory properties in the absence of virus infection, and the overexpression of P58 IPK results in malignant transformation (5) . Although the mechanism by which this occurs has not been defined, one possibility is that P58 IPK transforms cells by interfering with PKR-regulated pathways. There is a well-established correlation among PKR inhibition, reduced eIF-2␣ phosphorylation, and malignant transformation (4, 6, 13, 27, 37) . The stimulation of mRNA translation initiation rates, which occurs in response to decreased eIF-2␣ phosphorylation, may result in an increase in the translation of normally poorly translated mRNAs, such as those encoding growth factors or oncogenes. In addition, decreased eIF-2␣ phosphorylation may contribute to the suppression of apoptosis (44) , consistent with numerous reports that have implicated PKR as a mediator of programmed cell death pathways (3, 12, 30, 56, 57 rIPK , contains homology to a segment of the molecular chaperone Hsp90, which is essential for the function of a variety of steroid hormone receptors, transcription factors, and protein kinases (39) . P58 IPK , through its interaction with Hsp40, Hsp70, and an Hsp90-related protein, therefore appears to be intimately tied to the molecular chaperone machinery and to cellular stress response pathways.
Given the emerging relationship between the molecular chaperone machinery and apoptosis (23, 24, 45) , and the numerous reports of the apoptotic functions of PKR (reviewed in reference 49), we sought to examine the role of P58
IPK as an inhibitor of the programmed cell death response and to determine whether this property could contribute to the ability of P58 IPK to malignantly transform cells. To this end, we generated NIH 3T3 cell lines expressing either wild-type P58 IPK or a P58 IPK deletion mutant, ⌬TPR6, that does not bind to PKR or inhibit its ability to phosphorylate eIF-2␣ (18, 50) , thus enabling us to evaluate whether P58 IPK also acts outside PKR-dependent pathways. We found that overexpression of wild-type P58 IPK inhibited the double-stranded RNA (dsRNA)-induced phosphorylation of eIF-2␣ and the activation of NF-B, whereas these PKR-dependent functions remained active in ⌬TPR6-expressing cells. Moreover, the P58 IPK cell line, but not the ⌬TPR6 cell line, was resistant to dsRNA-induced apoptosis. In contrast, both the P58 IPK and ⌬TPR6 cell lines were resistant to apoptosis induced by tumor necrosis factor alpha (TNF-␣). Significantly, both cell lines exhibited a transformed phenotype and induced tumor formation in nude mice. Thus, our findings suggest that inhibition of PKR is not a requirement for P58
IPK -induced transformation and that suppression of apoptosis may be a primary mechanism by which P58 IPK malignantly transforms cells. A model depicting the role of P58
IPK as a regulator of apoptosis is presented. (2) . Following a 20-h transfection period, the DNA mix was removed and replaced with fresh medium. This medium was removed after an additional 24-h incubation and replaced by medium supplemented with 600 g of G418 (Geneticin; Life Technologies, Inc., Gaithersburg, Md.) per ml. After 9 days of drug selection, G418-resistant cells were trypsinized and individual clones were harvested. Clonal cell lines were maintained in medium containing 400 g of G418 per ml.
MATERIALS AND METHODS

Construction
Preparation of polyclonal antiserum to P58 IPK . Purification of glutathione S-transferase (GST)-P58
IPK fusion protein was performed as described previously (31) . For the generation of a polyclonal antiserum to P58 IPK , New Zealand White rabbits were immunized with 100 g of GST-P58 IPK in 5 ml of incomplete Freund's adjuvant containing 100 g of N-acetylmuramyl-L-alanyl-D-isoglutamine. Two subsequent boosts of 100 g of GST-P58 IPK in incomplete Freund's adjuvant were administered at monthly intervals.
Immunoblot analysis. Monolayer cell lines or dissociated tumor cells were washed twice with ice-cold Hanks' balanced salt solution and lysed in Triton lysis buffer (10 mM Tris hydrochloride [pH 7.5], 50 mM KCl, 1 mM dithiothreitol, 2 mM MgCl 2 , aprotinin [100 g/ml], 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100). After sodium dodecyl sulfate-polyacrylamide gel electrophoresis, polypeptides were transferred to nitrocellulose membranes (54) and detected with the P58 IPK monoclonal antibody 2F8 (5) or with the P58 IPK polyclonal antibody described above.
eIF-2␣ phosphorylation analysis. The state of eIF-2␣ phosphorylation in cultured cells was determined by vertical-slab isoelectric focusing and immunoblotting. Cell lysates were prepared essentially as described previously (40) , but without BPA-1000 treatment. The 10,000 ϫ g supernatant (20 g of protein) was subjected directly to vertical-slab isoelectric focusing (without prior immunoprecipitation of eIF-2␣), and the resolved proteins were transferred to nitrocellulose membranes. After transfer, blots were blocked in phosphate-buffered saline (PBS) containing 10% (wt/vol) nonfat dried milk and 0.2% Tween 20. All incubations with antibody against eIF-2␣ were performed in PBS containing 0.1 to 0.2% Tween 20. Autoradiographs were analyzed by scanning laser densitometry to determine the ratio of phosphorylated to unphosphorylated eIF-2␣ in each sample. A change in the ratio in response to poly(I ⅐ C) is considered indicative of PKR activity.
Electrophoretic mobility shift assay (EMSA) for NF-B activation. Cells (80% confluent in 10-cm-diameter dishes) were incubated in serum-free medium for 18 h, after which they were stimulated with either poly(rI ⅐ rC) (100 g/ml) or TNF-␣ (10 ng/ml; Boehringer Mannheim Biochemicals, Indianapolis, Ind.). Whole-cell extracts were prepared as described previously (19) , with the exception that the 15,000 ϫ g supernatant material was not subjected to dialysis. To assay for activation of NF-B, 5 g of cell extract was incubated with 0.2 ng of a 32 P-labeled oligonucleotide encoding positive regulatory domain II (PRDII) in binding buffer [20 mM HEPES, 50 mM NaCl, 5 mM MgCl 2 , 10% glycerol, 1 mM dithiothreitol, 0.6 mM EDTA, 1.0 g of poly(dI ⅐ dC) per ml] for 20 min at room temperature. Protein-DNA complexes were resolved by native 5% polyacrylamide gel electrophoresis in 0.5ϫ TBE (1ϫ TBE is 90 mM Tris, 90 mM boric acid, and 2 mM EDTA). The gels were dried, and NF-B-DNA complexes were visualized by autoradiography.
Apoptosis assay. Cells (5 ϫ 10 5 /sample) were treated with poly(I ⅐ C) (1, 10, or 100 g/ml) together with actinomycin D (50 ng/ml) for 16 h. Apoptosis-induced DNA fragmentation was detected by the in situ labeling of DNA strand breaks with fluorescein dUTP and terminal deoxynucleotidyltransferase as described by the manufacturer (Boehringer Mannheim). Fluorescein incorporation was analyzed with a FACStar flow cytometer (Immunocytometry Systems; Becton Dickinson, Mountain View, Calif.). Alternatively, cells were treated with TNF-␣ (0.2 to 1.0 ng/ml) together with actinomycin D (50 ng/ml) for 16 h and analyzed for cell viability by trypan blue dye exclusion or for apoptosis-induced DNA laddering as described previously (12) .
Cell growth assays. The growth rate of exponential-phase cells was measured by seeding 2 ϫ 10 4 cells in DMEM supplemented with 10% FBS and 400 g of G418 per ml. The culture medium was changed every 3 days, and the doubling time was determined by counting cells at 2-day intervals. To determine cloning efficiency, 10 4 cells were suspended in medium containing 0.35% agarose and overlaid onto medium containing 0.5% agarose in 35-mm-diameter plates. Colonies were then counted 2 to 4 weeks after plating. Percent cloning efficiency is defined as the number of colonies present 2 to 4 weeks after plating, divided by the number of cells plated, multiplied by 100.
Injection of nude mice and propagation of tumor cell lines. Four-to six-weekold athymic mice (BALB/c nu/nu; Taconic Farms, Germantown, N.Y.), housed in a specific-pathogen-free environment, were injected subcutaneously in the right inguinal area with 2 ϫ 10 6 cells in 500 l of DMEM. Tumors were extracted from euthanized mice under aseptic conditions, washed four times in PBS to remove excess blood, fat, and necrotic tissue, and minced. The tumor pieces were then added to DMEM containing 0.5% collagenase-dispase (Sigma Chemical Co., St. Louis, Mo.) and were homogenized with a Dounce vessel, and the homogenate was incubated for 2 h at 37°C with gentle stirring. Dissociated cells were washed once with complete DMEM and seeded into plates for the generation of tumor cell lines.
RESULTS
A P58
IPK protein that lacks the sixth TPR motif does not inhibit phosphorylation of eIF-2␣. We reported previously on the construction and characterization of P58 IPK deletion mutants to determine the regions of P58 IPK required to inhibit PKR activity (50) . Using this approach, we demonstrated that a P58
IPK mutant lacking the sixth TPR motif, ⌬TPR6, was unable to bind to PKR (18) or to inhibit PKR-mediated eIF-2␣ phosphorylation in vitro (50) . This characteristic of ⌬TPR6 enabled us to generate a cell line that would allow us to evaluate the ability of P58
IPK to function outside PKR-dependent pathways. To generate stable cell lines, NIH 3T3 cells were transfected with a pcDNAI/NEO expression construct encoding the ⌬TPR6 protein. Control cell lines were generated in a similar fashion by using a pcDNAI/NEO construct encoding the wild-type bovine P58 IPK (31) or by using the pcDNAI/NEO vector alone (NEO). After selection for G418 resistance, multiple clones from each transfection were analyzed by immunoblotting for ⌬TPR6 or P58 IPK protein production. Using a P58 IPK polyclonal antibody that detects bovine P58 IPK but does not recognize the endogenous mouse protein, we confirmed that the bovine P58 IPK or ⌬TPR6 protein was produced in each of the clones examined (Fig. 1) Using a variety of biochemical and genetic techniques, we have previously demonstrated that ⌬TPR6 fails to interact with PKR (18) , disrupt the formation of PKR dimers (48), or inhibit PKR activity (50) . To confirm these results in stable cell lines, we used isoelectric focusing to resolve the phosphorylated and unphosphorylated forms of eIF-2␣ in the wild-type P58 IPK , ⌬TPR6, and NEO cell lines. In this assay, a change in the ratio of phosphorylated to unphosphorylated eIF-2␣ in response to poly(I ⅐ C) is considered indicative of PKR activity. When treated with poly(I ⅐ C) to activate PKR, the P58 IPK cell line exhibited only a 1.3-fold increase in the ratio of phosphorylated to unphosphorylated eIF-2␣ ( Fig. 2 ; compare lane 2 to lane 1), indicating that PKR activity was inhibited by the overexpression of wild-type P58
IPK . In contrast, the ⌬TPR6 cell line exhibited a 4.5-fold increase in the ratio of phosphorylated to unphosphorylated eIF-2␣ ( Fig. 2 ; compare lane 4 to lane 3), demonstrating that PKR is active in ⌬TPR6-expressing cells. A 4.5-fold change in the ratio of phosphorylated to unphosphorylated eIF-2␣ was also observed in NEO cells. Thus, consistent with our earlier in vitro studies, a P58 IPK mutant that lacks the sixth TPR motif is also unable to block PKR-mediated eIF-2␣ phosphorylation in vivo. P58 IPK , but not ⌬TPR6, inhibits the dsRNA-induced activation of NF-B. Given the multiple functions of PKR, we next sought to evaluate the ability of P58 IPK to inhibit additional PKR-dependent pathways. PKR is essential for the dsRNAinduced activation of the transcriptional regulator NF-B (28, 34, 55) . We therefore began by examining whether the ability of dsRNA to induce activation of NF-B was altered in the P58 IPK or ⌬TPR6 cell line. An EMSA was used to detect NF-B DNA-binding activity as a measure of NF-B activation. We found that when NEO cells were treated with poly (I ⅐ C), there was an increase in NF-B DNA-binding activity ( Fig. 3; compare lanes 1 and 2) . Similarly, in ⌬TPR6-expressing cells, poly(I ⅐ C) treatment also resulted in activation of NF-B, but to an even greater extent than that observed in NEO cells, indicating a functional dsRNA signaling pathway (Fig. 3, lanes 7 and 8) . In contrast, poly(I ⅐ C) treatment did not appear to increase NF-B activation in P58
IPK -overexpressing cells (Fig. 3, lanes 4 and 5) . This observation suggests that P58
IPK not only inhibits PKR's ability to phosphorylate eIF-2␣ but also can block the ability of PKR to activate NF-B. It should be noted, however, that the effect of poly(I ⅐ C) on NF-B activation in P58
IPK -overexpressing cells may be somewhat obscured, since P58
IPK -overexpressing cells exhibited a high basal level of NF-B activation even in the absence of poly (I ⅐ C) ( Fig. 3; compare lane 1 to lane 4) . This effect was observed in multiple P58
IPK cell lines (data not shown) and may be similar to the increase in NF-B-dependent gene expression that also occurs in response to the expression of oncogenic forms of Ras, Raf-1, or Neu (ErbB-2/HER2) (14) (15) (16) .
As an alternative method of activating NF-B, we treated each of the cell lines with TNF-␣. In contrast to the effect observed with poly(I ⅐ C), treatment with TNF-␣ resulted in a marked increase in NF-B DNA-binding activity in both the ⌬TPR6 and P58
IPK cell lines (Fig. 3) . This result demonstrates that activation of NF-B, in response to an inducer other than dsRNA, is not impaired in P58 IPK -overexpressing cells. Moreover, the ability of P58
IPK to inhibit NF-B activation is specific for dsRNA signaling pathways. These findings are consistent with those of previous studies, which found that the elimination of PKR (through gene knockout, targeted mRNA ablation, or expression of a transdominant negative PKR mutant) impairs the ability of poly(I ⅐ C) to induce NF-B activation but has no effect on the ability of TNF-␣ to activate NF-B (12, 34, 44, 55) . Again, this effect was observed in multiple P58
IPK and ⌬TPR6 cell lines (data not shown).
P58
IPK , but not ⌬TPR6, mediates resistance to dsRNA-induced apoptosis. Since PKR has been implicated as a mediator of the apoptotic pathway that is activated in cells upon treatment with dsRNA (3, 12, 44), we examined the ability of dsRNA to induce apoptosis in the NEO, ⌬TPR6, and P58 IPK cell lines. For these experiments, cells were treated with poly (I ⅐ C), and apoptosis-induced DNA fragmentation was detected by the in situ labeling of DNA strand breaks with fluorescein dUTP and terminal deoxynucleotidyltransferase. We found that treatment with poly(I ⅐ C) induced apoptosis in a dose-dependent manner in both the NEO and ⌬TPR6 cell lines. When ⌬TPR6-expressing cells were treated with poly (I ⅐ C) at a concentration of 10 g/ml, 77% of the cells underwent apoptosis, and 85% of the cells became apoptotic at a poly(I ⅐ C) concentration of 100 g/ml (Fig. 4) . Thus, ⌬TPR6 does not inhibit the ability of PKR to mediate dsRNA-induced apoptosis. In contrast, only 9% of P58 IPK -overexpressing cells underwent apoptosis when treated with poly(I ⅐ C) at a concentration of 10 g/ml. Even at a 10-fold higher concentration of poly(I ⅐ C), only 35% of P58 IPK -overexpressing cells underwent apoptosis. These observations were consistent in multiple clonal cell lines and further extend the role of P58 IPK as a regulator of multiple PKR-dependent functions. IPK -1, ⌬TPR6-1, or NEO cells in mid-log phase, and 20 g of each extract was subjected to vertical-slab isoelectric focusing. The resolved proteins were transferred to a nitrocellulose membrane, and the blot was probed with an eIF-2␣ monoclonal antibody. The ratio of phosphorylated to unphosphorylated eIF-2␣ in each lane was determined by scanning laser densitometry. A change in the ratio in response to treatment with poly(I ⅐ C) is indicative of PKR activity. The ratio of phosphorylated to unphosphorylated eIF-2␣ increased 1.3-fold in the P58 IPK cell line and 4.5-fold in the ⌬TPR6 and NEO cell lines. Phosphorylated (P) and unphosphorylated forms of eIF-2␣ are indicated by arrows.
FIG. 3. P58
IPK , but not ⌬TPR6, inhibits the dsRNA-induced activation of NF-B. NF-B DNA-binding activities in NEO, P58
IPK -1, and ⌬TPR6-1 cell lines are shown. Cells were treated with medium alone, medium containing poly (I ⅐ C) (100 g/ml), or medium containing TNF-␣ (10 ng/ml). NF-B activation was detected in an EMSA using a 32 P-labeled PRDII oligonucleotide probe. NF-B-PRDII complexes are indicated by the arrow.
P58
IPK and ⌬TPR6 cell lines are resistant to TNF-␣-induced apoptosis. To extend these observations, and to determine if P58
IPK might function as a more general apoptotic inhibitor, we examined the ability of TNF-␣ to induce apoptosis in the P58 IPK and ⌬TPR6 cell lines. Microscopic examination revealed that in response to TNF-␣, only 20% of NEO cells remained viable, whereas the P58 IPK and ⌬TPR6 cell lines each maintained 75% cell viability (Fig. 5A) . The loss of viability in NEO cells was confirmed to be due to apoptosis by the presence of extensive DNA laddering (Fig. 5B) , a characteristic apoptotic signature of DNA cleavage into oligonucleosomesized fragments. In contrast, even at a TNF-␣ concentration of 1.0 ng/ml, DNA laddering was not detected in either the P58 IPK or the ⌬TPR6 cell line. It should be noted that since both cell lines showed activation of NF-B in response to TNF-␣ (Fig.  3) , resistance to TNF-␣-induced apoptosis did not reflect an inability to respond to this cytokine. Moreover, the recent report that PKR 0/0 cells exhibit no defect in the apoptotic response to TNF-␣ (1) indicates that the ability of P58 IPK (and ⌬TPR6) to mediate resistance to TNF-␣-induced apoptosis is not mediated through inhibition of PKR. Rather, it appears that P58 IPK may function to prevent cells from undergoing programmed cell death in response to a variety of inducers, establishing a novel role for P58
IPK as an inhibitor of apoptosis. ⌬TPR6-expressing cells exhibit a transformed phenotype and are tumorigenic in nude mice. Our observation that ⌬TPR6 was unable to inhibit PKR-dependent functions but acted as a suppressor of TNF-␣-induced apoptosis prompted us to examine whether ⌬TPR6 retained additional growth-regulatory properties. Microscopic examination revealed that, like the P58 IPK cell line, ⌬TPR6-expressing cells exhibited spindleshaped morphology and increased refractivity ( Fig. 6B and C) . Consistent with these morphological changes, transformed foci readily formed on top of ⌬TPR6 cell monolayers (Fig. 6F) , and ⌬TPR6-expressing cells grew faster and to a higher saturation density than the NEO cell line (Table 1) . Most significantly, the ⌬TPR6 cell line formed colonies in soft agar, indicating anchorage-independent growth (Fig. 6I) . We noted, however, that ⌬TPR6-expressing cells were approximately twofold less efficient at forming colonies in soft agar than cells overexpressing wild-type P58 IPK (Table 1) . Thus, although ⌬TPR6-expressing cells exhibit the characteristics of a transformed phenotype, this phenotype is less pronounced than that observed in the wild-type P58 IPK cell line. As a further test of the transforming properties of ⌬TPR6, we examined whether ⌬TPR6-expressing cells could form tumors in nude mice. For these studies, BALB/c nu/nu mice were injected in the right inguinal area with 2 ϫ 10 6 ⌬TPR6-expressing cells per animal. As controls, additional animals were injected with P58 IPK or NEO cells. As observed previously (5), mice injected with P58
IPK -overexpressing cells developed tumors approximately 2 weeks after injection (Table 1 ). In ac-
FIG. 4. P58
IPK , but not ⌬TPR6, mediates resistance to dsRNA-induced apoptosis. An analysis of dsRNA-induced apoptosis in NEO, ⌬TPR6-1, and P58 IPK -1 cell lines was performed. Cells were treated with poly(I ⅐ C) (1, 10, or 100 g/ml) for 16 h. Apoptosis-induced DNA fragmentation was detected by the labeling of DNA strand breaks with fluorescein dUTP and deoxynucleotidyltransferase. The percentage of apoptotic cells was quantified by flow cytometry as described in Materials and Methods.
cord with their transformed phenotype, mice injected with ⌬TPR6-expressing cells also developed tumors, although with a longer latency period. No tumors were observed in mice injected with NEO cells. To verify that the tumors produced either ⌬TPR6 or the wild-type bovine P58 IPK protein, cellular extracts were prepared from tumor homogenates and analyzed by immunoblotting. In each case, a high level of ⌬TPR6 or P58 IPK protein production was observed (Fig. 7, left panel) . To confirm that P58 IPK or ⌬TPR6 was responsible for inducing tumor formation, we generated tumor-derived cell lines by culturing excised tumors and selecting for G418-resistant cells. When analyzed by immunoblotting, cell lines derived from P58 IPK tumors showed a high level of bovine P58 IPK protein production. However, a comparatively low level of the ⌬TPR6 protein was produced in cell lines derived from ⌬TPR6 tumors (Fig. 7, right panel) . This low level of ⌬TPR6 may reflect an instability of the ⌬TPR6 protein or a downregulation of ⌬TPR6 mRNA expression during cell culture. Nevertheless, cell lines derived from ⌬TPR6 tumors were capable of inducing rapid tumor formation when injected into a second round of nude mice (Table 1) . Together, these results demonstrate that cells expressing a P58 IPK mutant that lacks the ability to inhibit PKR are tumorigenic in nude mice, indicating that inhibition of PKR is not an absolute requirement for P58 IPKinduced malignant transformation. Rather, it appears that P58 IPK also functions in a PKR-independent manner to malignantly transform cells.
DISCUSSION
In the present report, we have established that P58 IPK , originally identified as a cellular inhibitor of PKR, clearly has biological properties independent of the PKR pathway. We have found that P58
IPK is an antiapoptotic protein, able to mediate inhibition of programmed cell death in response to both TNF-␣ and dsRNA signaling. Utilization of cell lines expressing the P58 IPK deletion mutant ⌬TPR6 has allowed us to further elucidate the complex molecular pathways involving the P58 IPK cochaperone. In our model, we suggest that P58 IPK functions through at least two separate pathways to mediate resistance to apoptosis (Fig. 8) . In response to dsRNA, wildtype P58 IPK , but not ⌬TPR6, can inhibit PKR-mediated NF-B activation and eIF-2␣ phosphorylation. These events lead to a repression of apoptosis through pathways that may involve death effector caspases (3) or deregulation of the translation of mRNAs encoding proapoptotic proteins (44) . In con- trast to dsRNA-mediated events, both wild-type P58 IPK and the ⌬TPR6 mutant can inhibit apoptosis in response to TNF-␣. Based on studies with PKR-null mice (1, 12) and the work presented in this report, it is probable that TNF-␣ signals primarily through PKR-independent pathways, although one cannot completely rule out a minor PKR involvement. It is tempting to speculate, therefore, that P58
IPK and ⌬TPR6 suppress apoptosis by blocking an event upstream of PKR. For example, P58
IPK may disrupt the recruitment or activation of an upstream caspase, such as caspase 8 (FLICE) , which is at the apex of the TNF-␣-mediated apoptotic cascade (11) . This step in the apoptotic pathway is also a key point for inhibition by a variety of viral antiapoptotic proteins, collectively referred to as FLIPs (FLICE-inhibitory proteins) (7, 53) . Together, our results indicate that the ability of P58 IPK to suppress apoptosis may be a primary factor in P58
IPK -induced malignant transformation. In addition, the ability of wild-type P58 IPK to also inhibit PKR may account for the more-pronounced transformed phenotype observed in P58
IPK -overexpressing cells. Compared with the ⌬TPR6 cell lines, P58
IPK -overexpressing cells exhibited a higher cloning efficiency and faster tumor formation in nude mice.
The ability of P58 IPK to suppress apoptosis suggests that there may be parallels between P58
IPK and other antiapoptotic proto-oncogenes, such as Bcl-2. Interestingly, Bcl-2 blocks both influenza virus-induced and PKR-mediated apoptosis (22, 30) , but in contrast to P58 IPK , it does not affect the ability of PKR to inhibit translation. Thus, Bcl-2 is most likely exerting its action downstream of PKR, at or before the point where the PKR-dependent and -independent pathways converge into a common (or core) cell death pathway. Intriguingly, the recently described cochaperone activities of P58 IPK may provide additional insight into the mechanism by which P58 IPK suppresses apoptosis. The ability of P58
IPK to bind to and regulate Hsp70 may provide a link between P58 IPK , the cellular chaperone machinery, and the programmed cell death response. This may be analogous to the link that has been proposed for the antiapoptotic protein BAG-1. BAG-1 interacts with and enhances the activity of Bcl-2, and like P58 IPK , BAG-1 interacts with the ATPase domain of Hsp70 (23, 24, 45) . Thus, the cochaperone activities of P58 IPK may facilitate the interaction of P58 IPK , and possibly Hsp70, with one or more essential components of the apoptotic pathway.
By functioning as a regulator of apoptosis, P58 IPK may be important not only in cellular antiproliferative pathways but also in the cellular response to influenza virus infection. We demonstrated previously that influenza virus recruits P58 IPK to downregulate PKR, thereby ensuring the efficient synthesis of viral proteins. Intriguingly, influenza virus infection induces apoptosis (22, 46) , and there is evidence for the involvement of PKR in this process (47) . Therefore, the activation of P58 IPK by influenza virus may also be a mechanism to inhibit or delay PKR-mediated apoptosis, thereby providing sufficient time for viral replication to occur. The ability to inhibit apoptosis is proving to be a general theme among many viruses, and a variety of viral antiapoptotic proteins have been identified (reviewed in references 20, 38, and 51). In addition to the inhibition of FLICE, discussed above, these viral proteins may either mimic the function of cellular antiapoptotic proteins or target various activators of apoptosis for inhibition. For instance, the E1B protein of adenovirus (25) and the KSbcl-2 protein of human herpesvirus 8 (9) are functional homologues of the cellular antiapoptotic protein Bcl-2. Alternatively, the papillomavirus E6 protein blocks apoptosis by targeting p53 for proteolysis (41) , and the cowpox virus CrmA protein is a specific inhibitor of caspases (43, 52) . The relationship between viral inhibition of PKR and apoptosis is also becoming apparent (49) . Infection with a vaccinia virus mutant that lacks the E3L gene, which encodes a dsRNA-binding protein that is a potent inhibitor of PKR activation, triggers an apoptotic response that is not observed in cells infected with the wildtype virus (26, 29) . There is also evidence that herpes simplex virus may utilize its ␥ 1 34.5 gene product to counteract both the translational regulatory and apoptotic activities of PKR. It appears that the ␥ 1 34.5 gene product interacts with and directs a cellular type-1 protein phosphatase to reverse PKR-mediated eIF-2␣ phosphorylation (21) . This prevents the shutoff of protein synthesis, an event that is associated with neuronal apo- IPK and ⌬TPR6 protein production was performed. (Left) Four tumors from mice injected with ⌬TPR6 cell lines (two from mice injected with ⌬TPR6-1-expressing cells, designated ⌬TPR6-1.1 and ⌬TPR6-1.2, and two from mice injected with ⌬TPR6-2-expressing cells, designated ⌬TPR6-2.1 and ⌬TPR6-2.2) and one tumor from a mouse injected with the P58 IPK -1 cell line (P58 IPK -1) were analyzed by using the anti-P58 IPK monoclonal antibody, 2F8 (5). (Right) Cell lines derived from ⌬TPR6-expressing and P58
IPK -overexpressing tumors were analyzed by immunoblotting using the P58 IPK polyclonal antibody. In each panel, cell extracts prepared from MDBK cells were used as a source of bovine P58 IPK protein to serve as a positive control (lane 1). Cell extracts prepared from the NEO cell line were analyzed in parallel as a negative control (lane 2).
FIG. 8. Model of P58
IPK suppression of apoptosis. PKR has been implicated as an essential component of the apoptotic pathway that is induced by dsRNA, and inhibition of PKR by overexpression of P58 IPK results in resistance to dsRNA-induced apoptosis. Consistent with the inability of ⌬TPR6 to inhibit PKR-dependent functions, ⌬TPR6-expressing cells undergo apoptosis in response to dsRNA treatment. In contrast, both the P58 IPK and ⌬TPR6 cell lines were resistant to TNF-␣-induced apoptosis. We propose that P58 IPK (and ⌬TPR6) can also act in a PKR-independent fashion to regulate the TNF-␣ pathway. This regulation most likely occurs at a point in the pathway that is upstream of PKR. Suppression of apoptosis may be a primary mechanism by which overexpression of P58 IPK induces malignant transformation. See Discussion for additional details.
ptosis (10) . Influenza virus, rather than encoding a viral gene product to inhibit apoptosis, may instead recruit P58 IPK . Thus, P58
IPK may represent a novel example of a cellular antiapoptotic protein being recruited by a virus to avoid the host's programmed cell death response.
